Close
CRUSADE cuantifica el riesgo de sangrado mayor
intrahospitalario (Retroperitoneal o HIC, caida del Hto>
12%...) independientemente del tipo de tratamiento
empleado, ayudándonos a establecer el riesgo de sangrado
basal de los pacientes con SCASEST.
Referencia:
The CRUSADE (Can Rapid risk stratification of Unstable angina patients
Suppress ADverse outcomes with Early implementation of the
ACC/AHA guidelines) Bleeding Score.
The CRUSADE bleeding Score combines 8 readily available variables (baseline hematocrit, creatinine
clearance, female sex, diabetes, peripheral vascular disease, signs of heart failure, systolic blood pressure, and heart rate
on admission) into a validated bleeding risk Score (range 1 to 100 points). This Score stratifies baseline bleeding risk across
quintiles: Very low risk (Score ≤20), low risk (21 to 30), moderate risk (31 to 40), high risk (41 to 50), and very high risk
(≥50). In CRUSADE, observed rates of major in-hospital bleeding across quintiles of risk were 3.1% (very low risk), 5.5%
(low risk), 8.6% (moderate risk), 11.9% (high risk), and 19.5% (very high risk). By providing an estimation of baseline
risk of bleeding, application of the CRUSADE bleeding Score will better equip providers to consider the safety and efficacy
implications of various treatment strategies for a patient with non–ST-segment elevation myocardial infarction.
Rate of major bleeding among patients treated with <2 vs ≥2 antithrombotic* drugs (across CRUSADE bleeding Score in the derivation cohort. * Antithrombotic defined as: antiplatelet(aspirin or clopidogrel), anticoagulant , GP IIb/IIIa.
Cerrar